Prosecution Insights
Last updated: November 04, 2026
Application No. 18/578,487

UNNATURAL AMINO ACID, AND USE THEREOF, RECOMBINANT PROTEIN CONTAINING SAME, AND RECOMBINANT PROTEIN CONJUGATE

Non-Final OA §103§DOUBLEPATENT
Filed
Jan 11, 2024
Priority
Jul 29, 2021 — nonprovisional of PCTCN2021109276
Examiner
SABILA, MERCY HELLEN
Art Unit
1654
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novocodex Biopharmaceuticals Co. Ltd.
OA Round
1 (Non-Final)
57%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
158 granted / 277 resolved
-3.0% vs TC avg
Strong +46% interview lift
Without
With
+46.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
55 currently pending
Career history
337
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
45.2%
+5.2% vs TC avg
§102
15.0%
-25.0% vs TC avg
§112
20.2%
-19.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 277 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed on and is a U.S. national Stage application under 35 U.S.C. 371 of International Patent Application No. PCT/CN2021/109276 07/29/2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statements submitted on 01/11/2024, 11/01/2024, 12/16/2024, 05/14/2025, 09/15/2025 and 10/30/2025 have been considered by the examiner. Election/Restrictions Claims 6-10, 16-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected Group II-IV or based on the elected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/28/2026. Applicant’s election without traverse of Group I drawn to an unnatural amino acid, in the reply filed on 08/28/2026 is acknowledged. After further review, Examiner rescinds the election of species requirement. Claim Status Claims 1-20 are pending. Claims 6-10, 16-20 are withdrawn. claims 1-5, and 11-15 are being examined on the merits in this office action. Claim Objections Claims 1-2, and 5 are objected to because of the following informalities: Claim 1 recites “when X, Z and A…”. the claim can amended to recite “wherein X, Z and A…”. Claim 2 recites “…at least oen…”. The claim can be amended to recite “…at least one…”. Claim 5 recites “…which is…”. The claim should be amended to recite “…selected from the group consisting of…”. Appropriate correction is required. Drawings The drawings are objected to because Fig. 8 A,B,C contain statements in the graph that are not legible. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-5, and 11-15 are rejected under 35 U.S.C. 103 as being unpatentable over Kandula (WO2014087367A2 – hereinafter “Kandula”). Kandula teaches a compound of formula I PNG media_image1.png 320 323 media_image1.png Greyscale wherein R2 is PNG media_image2.png 292 432 media_image2.png Greyscale , R3 is PNG media_image3.png 186 167 media_image3.png Greyscale and R4 is PNG media_image4.png 201 612 media_image4.png Greyscale (See claim 1). Examiner notes that the cited variables lead the compound PNG media_image5.png 317 445 media_image5.png Greyscale which comprises the instant structure of Formula I, wherein X and Z are CO and CH2, and A is a C6-C20 aryl. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine the variables taught by Kandula to arrive to the instant compound of Formula I. One of ordinary skill in the art would have had a reasonable expectation of success in combining the variables taught by Kandula to arrive to the instant compound since the Kandula teaches the instant core structure and the variables are selected from a finite number of derivatives thus arriving to the instant compound. The disclosures render obvious claims 1 and 3. Regarding claim 2, Kandula teaches a compound of formula I PNG media_image1.png 320 323 media_image1.png Greyscale wherein R2 is PNG media_image2.png 292 432 media_image2.png Greyscale , R3 is PNG media_image3.png 186 167 media_image3.png Greyscale and R4 is PNG media_image4.png 201 612 media_image4.png Greyscale (See claim 1). Examiner notes that the cited variables lead the compound PNG media_image5.png 317 445 media_image5.png Greyscale wherein at least one substituent is CH2. Regarding claims 4-5, Kandula teaches a compound of formula I PNG media_image1.png 320 323 media_image1.png Greyscale wherein R2 is PNG media_image2.png 292 432 media_image2.png Greyscale , R3 is PNG media_image3.png 186 167 media_image3.png Greyscale and R4 is PNG media_image4.png 201 612 media_image4.png Greyscale (See claim 1). Examiner notes that the cited variables lead the compound PNG media_image5.png 317 445 media_image5.png Greyscale which reads on the instant compound (1-5) and compound 6 in claim 5, and wherein X is C0-C6 linear alkylene, and R1 and R2 is H. Regarding claim 11-13, Kandula teaches a compound of formula I PNG media_image1.png 320 323 media_image1.png Greyscale wherein R2 is PNG media_image2.png 292 432 media_image2.png Greyscale , R3 is PNG media_image3.png 186 167 media_image3.png Greyscale and R4 is PNG media_image4.png 201 612 media_image4.png Greyscale (See claim 1). Examiner notes that the cited variables lead the compound PNG media_image5.png 317 445 media_image5.png Greyscale which comprises the instant structure of Formula I, wherein X and Z are CO and CH2, and A is a C6-C20 aryl. Regarding claim 14-15, Kandula teaches a compound of formula I PNG media_image1.png 320 323 media_image1.png Greyscale wherein R2 is PNG media_image2.png 292 432 media_image2.png Greyscale , R3 is PNG media_image3.png 186 167 media_image3.png Greyscale and R4 is PNG media_image4.png 201 612 media_image4.png Greyscale (See claim 1). Examiner notes that the cited variables lead the compound PNG media_image5.png 317 445 media_image5.png Greyscale which comprises the instant structure of Formula I, wherein X and Z are CO and CH2, and A is a C6-C20 aryl. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-5, 11-15 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3-6, 12-16 of copending Application No. 18/687,680. Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims recite an unnatural amino acid of formula I PNG media_image6.png 117 422 media_image6.png Greyscale PNG media_image7.png 250 941 media_image7.png Greyscale The instant claims recite an unnatural amino acid, wherein the unnatural amino acid is a compound with a structure as shown in formula (I) or an enantiomer thereof, PNG media_image8.png 123 457 media_image8.png Greyscale PNG media_image9.png 458 980 media_image9.png Greyscale (claim 1). The copending claims anticipate the instant claims. Regarding claim 2, the copending claims recite wherein the substituent is selected from one or more of hydroxyl, sulfhydryl, halogen, nitro, cyano, C1-C6 alkyl, C1-C6 alkoxy, acyl, acylamino, carboxyl, ester, amino, sulfonyl, sulfinyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, C6-C20 aryl and C4-C10 heteroaryl (claim 3). Regarding claim 3, the copending claims recite wherein the unnatural amino acid is PNG media_image10.png 121 410 media_image10.png Greyscale (claim 4). Regarding claim 4, the copending claims recite wherein the unnatural amino acid are the compounds 1-3 to 1-6 (claim 5). Regarding claim 5, the copending claims recite the unnatural amino acid are the compounds 1-7 (claim 6) Regarding claim 11, the copending claims recite wherein X and Z each independently represent C0-C10 linear or branched alkylene; and/or A represents substituted or unsubstituted C6-C10 aryl (claim 12). Regarding claim 12, the copending claims recite wherein X and Z each independently represent CO-C6 linear alkylene, and one or more -CH2- are optionally substituted by one or more of -0-, -S- and -NH-; and/or A represents substituted or unsubstituted phenyl or naphthyl (claim 13). Regarding claim 13, the copending claims recite wherein X and Z are not CO alkylene simultaneously (claim 14). Regarding claim 14, the copending claims recite wherein the unnatural amino acid is a compound with a structure as shown in formula (1-2) PNG media_image11.png 317 917 media_image11.png Greyscale (claim 15). Regarding claim 15, the copending claims recite wherein X' represents CO-C4 linear alkylene, and one or more -CH2- are optionally substituted by -O- and/or -NH- (claim 16). Claims 1-3, 11-12 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3-4, of copending Application No. 18/687,683. Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims recite an unnatural amino acid of formula I PNG media_image12.png 141 495 media_image12.png Greyscale PNG media_image13.png 307 1117 media_image13.png Greyscale The instant claims recite an unnatural amino acid, wherein the unnatural amino acid is a compound with a structure as shown in formula (I) or an enantiomer thereof, PNG media_image8.png 123 457 media_image8.png Greyscale PNG media_image9.png 458 980 media_image9.png Greyscale (claim 1). Examiner notes that methyl group before the L variable corresponds to the instant Z variable, copending L variable corresponds to the instant A variable, and the copending X and Y variables correspond to the instant X and Y. Examiner further notes that copending claims recite that L can be an acyl which reads on a phenyl group. The copending claims anticipate the instant claims 1 and 3. Regarding claim 2, the copending claims recite wherein the substituent is selected from one or more of hydroxyl, sulfhydryl, halogen, nitro, cyano, C1-C6 alkyl, C1-C6 alkoxy, acyl, acylamino, carboxyl, ester, amino, sulfonyl, sulfinyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, C6-C20 aryl and C4-C10 heteroaryl and that X represents -0-, -S-, -NH- or -CH2-; and/or Y represents -C(O)- (claim 3). Regarding claims 11-12, the copending claims recite an unnatural amino acid of formula I PNG media_image12.png 141 495 media_image12.png Greyscale wherein Y is an aryl, which includes phenyl, and X is -CH2-, and Y is -C(O)- (claims 1, 3-4) which would read on the instant claims 11-12. Claims 1-3, 11-12 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4, of copending Application No. 18/292,767. Although the claims at issue are not identical, they are not patentably distinct from each other because the copending claims recite an unnatural amino acid of formula I PNG media_image12.png 141 495 media_image12.png Greyscale PNG media_image13.png 307 1117 media_image13.png Greyscale The instant claims recite an unnatural amino acid, wherein the unnatural amino acid is a compound with a structure as shown in formula (I) or an enantiomer thereof, PNG media_image8.png 123 457 media_image8.png Greyscale PNG media_image9.png 458 980 media_image9.png Greyscale (claim 1, 3). Examiner notes that methyl group before the L variable corresponds to the instant Z variable, copending L variable corresponds to the instant A variable, and the copending X and Y variables correspond to the instant X and Y. Examiner further notes that copending claims recite that L can be an acyl which reads on a phenyl group. The copending claims anticipate the instant claims 1 and 3. Regarding claim 2, the copending claims recite wherein the substituent is selected from one or more of hydroxyl, sulfhydryl, halogen, nitro, cyano, C1-C6 alkyl, C1-C6 alkoxy, acyl, acylamino, carboxyl, ester, amino, sulfonyl, sulfinyl, C3-C8 cycloalkyl, C3-C8 heterocyclyl, C6-C20 aryl and C4-C10 heteroaryl and that X represents -0-, -S-, -NH- or -CH2-; and/or Y represents -C(O)- (claim 2). Regarding claims 11-12, the copending claims recite an unnatural amino acid of formula I PNG media_image12.png 141 495 media_image12.png Greyscale wherein Y is an aryl, which includes phenyl, and X is -CH2-, and Y is -C(O)- (claims 1-4) which would read on the instant claims 11-12. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mercy H. Sabila whose telephone number is (571)272-2562. The examiner can normally be reached Monday - Friday 5:00 am - 3:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lianko G. Garyu can be reached at (571)270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MERCY H SABILA/Examiner, Art Unit 1654 /LIANKO G GARYU/Supervisory Patent Examiner, Art Unit 1654
Read full office action

Prosecution Timeline

Jan 11, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697366
THERMOGENIC COMPOSITIONS AND METHODS
5y 0m to grant Granted Aug 04, 2026
Patent 12662492
SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF
5y 9m to grant Granted Jun 23, 2026
Patent 12629410
MULTI-ANTIGENIC PEPTIDE MIMICS OF GONOCOCCAL LIPO-OLIGOSACCHARIDE (LOS) EPITOPES
4y 2m to grant Granted May 19, 2026
Patent 12617831
PEPTIDE TARGETING GIP AND GLP-2 RECEPTORS FOR TREATING BONE DISORDERS
4y 8m to grant Granted May 05, 2026
Patent 12618847
ACTIVITY-BASED PROBES WITH UNNATURAL AMINO ACIDS TO MONITOR PROTEASOME ACTIVITY
3y 8m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
57%
Grant Probability
99%
With Interview (+46.2%)
2y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 277 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month